[go: up one dir, main page]

MX2010001076A - Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico. - Google Patents

Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico.

Info

Publication number
MX2010001076A
MX2010001076A MX2010001076A MX2010001076A MX2010001076A MX 2010001076 A MX2010001076 A MX 2010001076A MX 2010001076 A MX2010001076 A MX 2010001076A MX 2010001076 A MX2010001076 A MX 2010001076A MX 2010001076 A MX2010001076 A MX 2010001076A
Authority
MX
Mexico
Prior art keywords
tetrahydropyrrolo
nr7r8
carboxamide
c6alkyl
alkyl
Prior art date
Application number
MX2010001076A
Other languages
English (en)
Inventor
Arielle Genevois-Borella
Jean-Luc Malleron
Michel Evers
Bernard Baudoin
Andreas Karlsson
Magali Mathieu
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0705498A external-priority patent/FR2919289B1/fr
Priority claimed from FR0705497A external-priority patent/FR2919288B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010001076A publication Critical patent/MX2010001076A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a derivados de 1 2,3,4-tetrahidropirrolo[1 ,2-a]pirazina-6-carboxamida y 2,3,4,5- tetrahidropirrolo[1 ,2-a][1 ,4]-diazepina-7-carboxamida de fórmula general (I), donde R1 = H, alquilo de 1 a 10 átomos de carbono, cicloalquilo de 3 a 7 átomos de carbono, (CH2)n-aIquenilo(1 a 6 átomos de carbono), (CH2)n-alquinilo(1 a 6 átomos de carbono), alquilo de 1 a 6 átomos de carbono-Z-alquilo(de 1 a 6 átomos de carbono), donde Z = un heteroátomo elegido de O, N y S(O)m, o R1 = un grupo COOR, S(O)mR, arilo o aralquilo; R2 = uno o varios grupos H, halógeno, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 7 átomos de carbono, alquenilo de 1 a 6 átomos de carbono, alquinilo de 1 a 6 átomos de carbono, alquilo de 1 a 6 átomos de carbono-Z-alquilo(de 1 a 6 átomos de carbono), donde Z = un heteroátomo de O, N y S (O) m, o R2 = halo-alquilo(de 1 a 6 átomos de carbono), halo-alcoxi(de 1 a 6 átomos de carbono), hidroxi, alcoxi de 1 a 6 átomos de carbono, nitro, ciano, amino, NR7R8, COOR, C(O)NR7R8, O-C(O)alquilo(de a 6 átomos de carbono), S(O)m-NR7R8, arilo; R3 = trifluorometilo; R4 y R5 independientemente = H, o R4 y R5 forman un anillo saturado con el carbono al cual se unen con 3 a 6 C opcionalmente que contienen O a 1 heteroátomos de O, N o S; R6 = H, halógeno, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 7 átomos de carbono, nitro, amino, NR7R8, COOR, arilo, NR7(SO2)R8 o C(O)NR7R8 W = metileno o C(O); m = un m = un número entero entre O y 2, n = un número entero entre 1 y 6, p = 2 ó 3. El método para producción y aplicación terapéutica.
MX2010001076A 2007-07-27 2008-07-24 Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico. MX2010001076A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705498A FR2919289B1 (fr) 2007-07-27 2007-07-27 Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR0705497A FR2919288B1 (fr) 2007-07-27 2007-07-27 Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
PCT/FR2008/001096 WO2009044007A2 (fr) 2007-07-27 2008-07-24 Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MX2010001076A true MX2010001076A (es) 2010-03-09

Family

ID=40526763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001076A MX2010001076A (es) 2007-07-27 2008-07-24 Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico.

Country Status (23)

Country Link
US (1) US20100197668A1 (es)
EP (1) EP2185561B1 (es)
JP (1) JP2010534639A (es)
KR (1) KR20100050485A (es)
CN (1) CN101765601A (es)
AT (1) ATE512968T1 (es)
AU (1) AU2008306835A1 (es)
BR (1) BRPI0813094A2 (es)
CA (1) CA2694288A1 (es)
CO (1) CO6290689A2 (es)
CY (1) CY1112121T1 (es)
DK (1) DK2185561T3 (es)
EA (1) EA201070195A1 (es)
HR (1) HRP20110650T1 (es)
MA (1) MA31630B1 (es)
MX (1) MX2010001076A (es)
NZ (1) NZ582871A (es)
PL (1) PL2185561T3 (es)
PT (1) PT2185561E (es)
RS (1) RS51912B (es)
SI (1) SI2185561T1 (es)
WO (1) WO2009044007A2 (es)
ZA (1) ZA201000581B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919285B1 (fr) * 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
US8822527B2 (en) 2011-10-17 2014-09-02 Biotheryx, Inc. Substituted biaryl alkyl amides
US9284333B2 (en) 2012-02-03 2016-03-15 Sanofi Fused pyrroledicarboxamides and their use as pharmaceuticals
WO2016068478A2 (ko) * 2014-10-30 2016-05-06 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
US10301306B2 (en) 2014-12-15 2019-05-28 Bristol-Myers Squibb Company Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
CN114522668B (zh) * 2022-01-13 2023-10-13 浙江大学杭州国际科创中心 乙氧基柱[6]芳烃晶体材料在选择性吸附四氢吡咯中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477117A1 (en) * 2002-02-22 2003-08-28 Teijin Limited Pyrrolopyrimidine derivative
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CA2694288A1 (fr) 2009-04-09
CN101765601A (zh) 2010-06-30
NZ582871A (en) 2011-09-30
CO6290689A2 (es) 2011-06-20
BRPI0813094A2 (pt) 2014-12-23
MA31630B1 (fr) 2010-08-02
HRP20110650T1 (hr) 2011-10-31
PL2185561T3 (pl) 2011-11-30
CY1112121T1 (el) 2015-11-04
US20100197668A1 (en) 2010-08-05
WO2009044007A2 (fr) 2009-04-09
EP2185561B1 (fr) 2011-06-15
DK2185561T3 (da) 2011-10-10
AU2008306835A1 (en) 2009-04-09
ATE512968T1 (de) 2011-07-15
PT2185561E (pt) 2011-09-07
JP2010534639A (ja) 2010-11-11
KR20100050485A (ko) 2010-05-13
SI2185561T1 (sl) 2011-10-28
EA201070195A1 (ru) 2010-10-29
ZA201000581B (en) 2011-04-28
RS51912B (sr) 2012-02-29
EP2185561A2 (fr) 2010-05-19
WO2009044007A3 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
MX2010001076A (es) Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico.
JP6527534B2 (ja) ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
DOP2007000092A (es) Derivados de cicloalquilaminoácidos
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
UA87416C2 (ru) Гетероциклические амиды, композиция на их основе и способ борьбы с заражением полезных растений фитопатогенными микроорганизмами и его предупреждение, промежуточные соединения
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
TW200720252A (en) Cyclic amine derivative having substituted alkyl group
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
WO2008145839A8 (fr) Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
WO2008038136A3 (en) Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
WO2005040345A3 (en) 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
MY193754A (en) Treatment for parkinson's disease
EA201070196A1 (ru) Производные 1-оксо-1,2-дигидроизохинолин-5-карбоксамидов и 4-оксо-3,4-дигидрохиназолин-8-карбоксамидов, их получение и их применение в терапии
WO2009056707A8 (fr) Dérivés de l'ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique
HUP9700708A2 (hu) N-[(9-pirimido[1,2-a]indolil)-metil-fenil-acetil]-fenil-glicinol-származékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierjeik
EA200300915A1 (ru) Производные изоксазолина в качестве антидепрессантов

Legal Events

Date Code Title Description
FG Grant or registration